malignant pleural effusion

Summary

Summary: Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.

Top Publications

  1. Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29:829-38 pubmed
    ..Studies of malignant pleural effusion in humans were selected with no language restrictions applied...
  2. Toh C, Leong S, Thng C, Tan E. Unilateral breast edema in two patients with malignant pleural effusion. Tumori. 2004;90:501-3 pubmed
    ..We postulate a possible pathophysiology for the association between breast edema and malignant pleural effusion. The principle of management when one encounters similar cases would be to treat the underlying pleural ..
  3. Holloway A, Diyagama D, Opeskin K, Creaney J, Robinson B, Lake R, et al. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res. 2006;12:5129-35 pubmed
    ..or adenocarcinoma of the lung often present with respiratory complications associated with a malignant pleural effusion. Distinguishing between these malignancies is frequently problematic, as many of the clinical, cytologic,..
  4. Yang C, Lee J, Lee H, Shim T, Son J, Jung S, et al. Differential cytokine levels and immunoreactivities against Mycobacterium tuberculosis antigens between tuberculous and malignant effusions. Respir Med. 2008;102:280-6 pubmed
    ..These data indicate that selected mycobacterial antigens (ESAT-6 and MTB12) and cytokine markers (IFN-gamma, IL-12p40, and IL-6) provide useful information for differentiating tuberculous and malignant effusions in clinical practice...
  5. Margaritora S, Cesario A, Vita M, Granone P. Single versus multiple access video-assisted thoracic surgery in the treatment of malignant pleural effusion. Eur J Cardiothorac Surg. 2007;32:397; author reply 397-8 pubmed
  6. Lombardi G, Zustovich F, Nicoletto M, Donach M, Artioli G, Pastorelli D. Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. Am J Clin Oncol. 2010;33:420-3 pubmed publisher
    b>Malignant pleural effusion is a frequent complication in many types of tumors, and its presence indicates short expected survival. This review updates the current knowledge about diagnosis and management of malignant pleural effusion...
  7. Daniel C, Kriegel I, Di Maria S, Patrubani G, Levesque R, Livartowski A, et al. Use of a pleural implantable access system for the management of malignant pleural effusion: the Institut Curie experience. Ann Thorac Surg. 2007;84:1367-70 pubmed
    b>Malignant pleural effusion has a very poor prognosis, raises problems of medical management, and impairs quality of life...
  8. Liang Q, Shi H, Qin X, Liang X, Jiang J, Yang H. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax. 2008;63:35-41 pubmed
    ..The role of tumour markers such as carbohydrate antigen (CA) 125, CA 15-3, CA 19-9 and CYFRA 21-1 (a fragment of cytokeratin 19) in differentiating malignant pleural effusions (MPE) from benign effusions is not yet clear...
  9. Tremblay A. Tunnelled pleural catheters in malignant pleural effusion. Lancet. 2007;370:387; author reply 387 pubmed

More Information

Publications72

  1. Chen K, Liu W, Yang Y, Leu S, Shih N. Characterization of novel transforming growth factor-beta type I receptors found in malignant pleural effusion tumor cells. BMC Mol Biol. 2007;8:72 pubmed
    ..Expression of this mutant could interfere with endogenous TGFbeta signaling in the cell. However, little is known about the importance of the remaining part of the signal peptide on the cellular function of T beta RI...
  2. Neragi Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer. 2006;54:1-9 pubmed
    b>Malignant pleural effusion is a common and debilitating complication of advanced malignant diseases. This problem seems to affect particularly those with lung and breast cancer, contributing to the poor quality of life...
  3. Burgers J, Olijve A, Baas P. [Chronic indwelling pleural catheter for malignant pleural effusion in 25 patients]. Ned Tijdschr Geneeskd. 2006;150:1618-23 pubmed
    ..To describe the experience with an indwelling pleural catheter in patients with pleuritis carcinomatosa...
  4. Bazerbashi S, Villaquiran J, Awan M, Unsworth White M, Rahamim J, Marchbank A. Ambulatory intercostal drainage for the management of malignant pleural effusion: a single center experience. Ann Surg Oncol. 2009;16:3482-7 pubmed publisher
    ..We have reviewed our use of ambulatory drains (Pleurex drains) in this regard with particular reference to hospital stay, duration of drainage, and incidence of complications...
  5. Kim K, Choi H, Kang S, Park S, Jung D, Cho J, et al. The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer. Eur J Radiol. 2010;75:230-5 pubmed publisher
    The purpose of this study was to retrospectively assess possible clinical predictors of malignant pleural effusion in patients with ovarian cancer.
  6. Moschos C, Psallidas I, Kollintza A, Karabela S, Papapetropoulos A, Papiris S, et al. The angiopoietin/Tie2 axis mediates malignant pleural effusion formation. Neoplasia. 2009;11:298-304 pubmed
    ..In the present study, we aimed to examine the role of the angiopoietin/Tie2 axis in MPE pathogenesis...
  7. Efthymiou C, Masudi T, Thorpe J, Papagiannopoulos K. Malignant pleural effusion in the presence of trapped lung. Five-year experience of PleurX tunnelled catheters. Interact Cardiovasc Thorac Surg. 2009;9:961-4 pubmed publisher
    ..In a series of patients with malignant pleural effusion the medial survival time was 20 weeks, with 30 days and 1 year mortality rates of 12.8% and 83...
  8. Iankov I, Msaouel P, Allen C, Federspiel M, Bulur P, Dietz A, et al. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat. 2010;122:745-54 pubmed publisher
    ..Here, we demonstrate the therapeutic efficacy of measles virus (MV) vaccine strain derivative against malignant pleural effusion in an MDA-MB-231 xenograft model of advanced breast cancer. Both systemic intravenous (i.v...
  9. Katayama H, Hiraki A, Aoe K, Fujiwara K, Matsuo K, Maeda T, et al. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion. Int J Cancer. 2007;120:2191-5 pubmed
    ..6%, 79.4%, and 80.0% respectively. In conclusion, aberrant promoter methylation of tumor suppressor genes in pleural fluid DNA could be a valuable diagnostic marker for malignant pleural effusion.
  10. Abouzgheib W, Bartter T, Dagher H, Pratter M, Klump W. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. Chest. 2009;135:999-1001 pubmed publisher
    ..This is a prospective study to define the volume of pleural fluid adequate for maximal yield of cytologic analysis of pleural fluid...
  11. Gu P, Huang G, Chen Y, Zhu C, Yuan J, Sheng S. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal. 2007;21:398-405 pubmed
    ..There was no statistical significance between the AUC of CEA and CYFRA 21-1 (P>0.05). Both CEA and CYFRA 21-1 have good performance in the differential diagnosis of PE, when compared with CEA, CYFRA 21-1 has no advantage...
  12. Chen H, Brahmer J. Management of malignant pleural effusion. Curr Oncol Rep. 2008;10:287-93 pubmed
    b>Malignant pleural effusion (MPE) often presents in patients with cancer at an advanced stage and thus carries a poor prognosis...
  13. Stefani A, Natali P, Casali C, Morandi U. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study. Eur J Cardiothorac Surg. 2006;30:827-32 pubmed
    The aim of this study was to investigate the effectiveness, safety and appropriate mode of administration of intrapleural talc for pleurodesis, in the treatment of malignant pleural effusion (MPE).
  14. Stathopoulos G, Moschos C, Loutrari H, Kollintza A, Psallidas I, Karabela S, et al. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med. 2008;178:50-9 pubmed publisher
    ..The antitumor actions of aminobiphosphonates, including angiostasis, are relevant to the pathogenesis of malignant pleural effusion (MPE), but no study has addressed the efficacy of these compounds against malignant pleural disease.
  15. Heffner J. Diagnosis and management of malignant pleural effusions. Respirology. 2008;13:5-20 pubmed publisher
    ..Management is palliative with interventions directed towards decreasing the volume of intrapleural fluid and the severity of associated symptoms...
  16. Inan I, De Sousa S, Myers P, Bouclier B, Dietrich P, Hagen M, et al. Management of malignant pleural effusion and ascites by a triple access multi perforated large diameter catheter port system. World J Surg Oncol. 2008;6:85 pubmed publisher
    ..Pleural or peritoneal effusions (ascites) are frequent in terminal stage malignancies. Medical management may be hazardous...
  17. Sebastian M, Kiewe P, Schuette W, Brust D, Peschel C, Schneller F, et al. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. J Immunother. 2009;32:195-202 pubmed publisher
    ..efficacy in patients with malignant ascites, we performed this phase 1/2 trial in patients with malignant pleural effusion (MPE)...
  18. Fang F, Chen P, Wu X, Yang L, Yang X, Xi Z, et al. Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion. J Cancer Res Clin Oncol. 2009;135:1149-57 pubmed publisher
    b>Malignant pleural effusion (MPE) is a common clinical problem in patients with advanced cancer...
  19. Shi H, Liang Q, Jiang J, Qin X, Yang H. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology. 2008;13:518-27 pubmed publisher
    Conventional tests are not always helpful in making a diagnosis of malignant pleural effusion (MPE). Many studies have investigated the utility of pleural carcinoembryonic antigen (CEA) in the early diagnosis of MPE...
  20. Aydogmus U, Ozdemir S, Cansever L, Sonmezoglu Y, Kocaturk C, Bedirhan M. Bedside talc pleurodesis for malignant pleural effusion: factors affecting success. Ann Surg Oncol. 2009;16:745-50 pubmed publisher
    To determine the factors affecting the success of bedside talc slurry (TS) used for symptomatic treatment of patients with malignant pleural effusion (MPE).
  21. Janssen J, Collier G, Astoul P, Tassi G, Noppen M, Rodriguez Panadero F, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet. 2007;369:1535-9 pubmed
    Talc is the most effective chemical pleurodesis agent for patients with malignant pleural effusion. However, concerns have arisen about the safety of intrapleural application of talc, after reports of development of acute respiratory ..
  22. Cui R, Takahashi F, Ohashi R, Yoshioka M, Gu T, Tajima K, et al. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer. 2009;63:368-74 pubmed publisher
    b>Malignant pleural effusion (MPE) is associated with advanced-stage lung cancer and is a poor prognostic sign for these patients...
  23. Sioris T, Sihvo E, Salo J, Rasanen J, Knuuttila A. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis. Eur J Surg Oncol. 2009;35:546-51 pubmed publisher
    Talc pleurodesis using talc slurry via chest tube is a primary option in malignant pleural effusion, since life expectancy is short and surgical decortication is hazardous...
  24. Qin X, Shi H, Deng J, Liang Q, Jiang J, Ye Z. CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res. 2009;15:2231-7 pubmed publisher
    The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells ..
  25. Ozyurtkan M, Balci A, Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion. Eur J Intern Med. 2010;21:30-4 pubmed publisher
    b>Malignant pleural effusion (MPE) has a limited life expectancy (3-12 months). We investigated the predictors of the early mortality (EM) within three months.
  26. Warren W, Kim A, Liptay M. Identification of clinical factors predicting Pleurx catheter removal in patients treated for malignant pleural effusion. Eur J Cardiothorac Surg. 2008;33:89-94 pubmed
    ..In particular, clinical parameters were analyzed for their influence on catheter removeability...
  27. Psallidas I, Karabela S, Moschos C, Sherrill T, Kollintza A, Magkouta S, et al. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. Mol Cancer. 2010;9:56 pubmed publisher
    ..In the present studies we hypothesized that treatment of immunocompetent mice with bortezomib tailored to inhibit cancer cell NF-kappaB activation and not proliferation specifically inhibits MPE formation by LLC cells...
  28. Ye Z, Zhou Q, Gu Y, Qin S, Ma W, Xin J, et al. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J Immunol. 2010;185:6348-54 pubmed publisher
    ..some human cancers; however, the possible implication of Th17 cells in regulating antitumor responses in malignant pleural effusion (MPE) remains to be elucidated...
  29. Stathopoulos G, Psallidas I, Moustaki A, Moschos C, Kollintza A, Karabela S, et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst. 2008;100:1464-76 pubmed publisher
    ..Tumor cells in malignant pleural effusions (MPEs) are an important source of monocyte chemoattractant protein (MCP)-1. However, the role of tumor-derived MCP-1 in the pathogenesis and progression of MPE has not been determined...
  30. Musani A. Treatment options for malignant pleural effusion. Curr Opin Pulm Med. 2009;15:380-7 pubmed publisher
    Thirty percent of lung cancers eventually result in malignant pleural effusion (MPE). Devastating consequences of MPE, such as dyspnea and cough, severely deteriorate the quality of life of these patients...
  31. Olden A, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliat Med. 2010;13:59-65 pubmed publisher
    ..An alternative option is outpatient placement of the Pleurx catheter (Denver Biomedical Inc., Denver, CO) for home-based drainage of effusions...
  32. Fang F, Gong C, Qian Z, Zhang X, Gou M, You C, et al. Honokiol nanoparticles in thermosensitive hydrogel: therapeutic effects on malignant pleural effusion. ACS Nano. 2009;3:4080-8 pubmed publisher
    ..glycol) (PEG-PCL-PEG, PECE) hydrogel (HK-hydrogel) could improve the therapeutic efficacy on malignant pleural effusion (MPE)...
  33. Stathopoulos G, Sherrill T, Karabela S, Goleniewska K, Kalomenidis I, Roussos C, et al. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med. 2010;182:1273-81 pubmed publisher
    ..Because eosinophils can be found in malignant pleural effusions (MPE) from mice and humans, we asked whether IL-5 is involved in the pathogenesis of MPE...
  34. Zhang X, Zhao Y, Wang M, Yap W, Chang A. Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer. 2008;60:175-82 pubmed
    Cells or cell-free fluid of malignant pleural effusion could be important clinical specimen for epidermal growth factor receptor (EGFR) mutation screening in advanced non-small cell lung cancer (NSCLC) patients...
  35. Balassoulis G, Sichletidis L, Spyratos D, Chloros D, Zarogoulidis K, Kontakiotis T, et al. Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion. Am J Clin Oncol. 2008;31:384-9 pubmed publisher
    ..The purpose of this study was to evaluate the efficacy and safety of erythromycin as a pleural sclerosing agent...
  36. Basak S, Veena M, Oh S, Huang G, Srivatsan E, Huang M, et al. The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PLoS ONE. 2009;4:e5884 pubmed publisher
  37. Shimizu T, Takahashi N, Terakado M, Tsujino I, Hashimoto S. Activation of Valpha24NKT cells in malignant pleural effusion in patients with lung cancer. Oncol Rep. 2009;22:581-6 pubmed
    ..b>Malignant pleural effusion, a frequently occurring complication in patients with lung cancer, contains numerous lymphocytes...
  38. Davies H, Lee Y, Davies R. Pleurodesis for malignant pleural effusion: talc, toxicity and where next?. Thorax. 2008;63:572-4 pubmed publisher
  39. Afify A, Lynne L, Howell L. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions. Diagn Cytopathol. 2007;35:105-10 pubmed
    ..We conclude that the HA and sCD44v6 levels in body fluids correlate with the cytology diagnosis and could be used as an ancillary study in cytology to differentiate nonmalignant from malignant effusions...
  40. Stathopoulos G, Kollintza A, Moschos C, Psallidas I, Sherrill T, Pitsinos E, et al. Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res. 2007;67:9825-34 pubmed
    Tumor necrosis factor (TNF)-alpha is present in the microenvironment of human tumors, including malignant pleural effusion (MPE)...
  41. Barbetakis N, Samanidis G, Paliouras D, Tsilikas C. Re-expansion pulmonary edema following video-assisted thoracic surgery for recurrent malignant pleural effusion. Interact Cardiovasc Thorac Surg. 2008;7:532-4 pubmed publisher
    A rare case of a unilateral re-expansion pulmonary edema following video-assisted thoracic surgery for malignant pleural effusion is described.
  42. Verfaillie G, Herreweghe R, Lamote J, Noppen M, Sacre R. Use of a Port-a-Cath system in the home setting for the treatment of symptomatic recurrent malignant pleural effusion. Eur J Cancer Care (Engl). 2005;14:182-4 pubmed
    ..The main advantage of this technique is the fact that the procedure of drainage can be performed by a nurse in the home setting. ..
  43. Yildirim E, Dural K, Yazkan R, Zengin N, Yildirim D, Gunal N, et al. Rapid pleurodesis in symptomatic malignant pleural effusion. Eur J Cardiothorac Surg. 2005;27:19-22 pubmed
    ..whether a rapid method of pleurodesis was superior to the standard protocol in patients with symptomatic malignant pleural effusion. Between January 2000 and February 2003, a prospective randomised trial was carried out in a sequential ..
  44. Saisho S, Saeki T, Takashima S, Aogi K, Ohsumi S. [Local administration of adriamycin (ADM) for malignant pleural effusion and pericardiac effusion in breast cancer]. Gan To Kagaku Ryoho. 2003;30:2063-8 pubmed
    ..toxicity, and survival rate of patients treated with local administration of adriamycin (ADM) for malignant pleural effusion and pericardial effusion in breast cancer...
  45. Porcel J, Vives M. Etiology and pleural fluid characteristics of large and massive effusions. Chest. 2003;124:978-83 pubmed
    ..Bloody pleural fluid with low ADA content favors a malignant condition. ..
  46. Chen Y, Tsai C, Whang Peng J, Perng R. Double signal stimulation was required for full recovery of the autologous tumor-killing effect of effusion-associated lymphocytes. Chest. 2002;122:1421-7 pubmed
    ..The depressed cellular function of EAL could be reversed with double signal stimulation, including IL-2 plus IL-7, IL-2 plus IL-12, or IL-2 plus TCR-CD3 engagement. These recovered cellular functions were mainly from CD8(+) CTL. ..
  47. Ohm C, Park D, Vogen M, Bendick P, Welsh R, Pursel S, et al. Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions. Am Surg. 2003;69:198-202; discussion 202 pubmed
    Therapy for recurrent malignant pleural effusion (MPE) is palliative. Video-assisted thoracic surgery with talc pleurodesis (VATS/TP) is limited to inpatients with completely expandable lung parenchyma...
  48. Antunes G, Neville E, Duffy J, Ali N. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58 Suppl 2:ii29-38 pubmed
  49. Villena V, Lopez Encuentra A, Garcia Lujan R, Echave Sustaeta J, Martínez C. Clinical implications of appearance of pleural fluid at thoracentesis. Chest. 2004;125:156-9 pubmed
    ..Almost half of BPEs were secondary to neoplasms, but only 11% of the neoplastic effusions were BPEs. Other common causes of BPE were parapneumonic and posttraumatic. ..
  50. Schulze M, Boehle A, Kurdow R, Dohrmann P, Henne Bruns D. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg. 2001;71:1809-12 pubmed
    For effective palliation of patients with malignant pleural effusion due to advanced neoplastic disease, any proposed treatment should have low procedure-related mortality and morbidity.
  51. Su W, Lai W, Chen H, Hsiue T, Chen C, Huang W, et al. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study. Oncology. 2003;64:18-24 pubmed
    Patients with non-small-cell lung cancer (NSCLC) and malignant pleural effusion (MPE) are difficult to manage clinically and have a short life expectancy. In this pilot study, we designed a protocol of combined intrapleural (i.p...
  52. Pien G, Gant M, Washam C, Sterman D. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. Chest. 2001;119:1641-6 pubmed
    We describe a series of patients with symptomatic, refractory malignant pleural effusion (MPE) and underlying trapped lung syndrome who underwent placement of a small-bore, flexible indwelling pleural catheter for home drainage of ..
  53. Kuzdzał J, Sładek K, Wasowski D, Soja J, Szlubowski A, Reifland A, et al. Talc powder vs doxycycline in the control of malignant pleural effusion: a prospective, randomized trial. Med Sci Monit. 2003;9:PI54-9 pubmed
    b>Malignant pleural effusion is a common problem in advanced cancers, contributing to the poor quality of life in this group of patients...
  54. Dresler C, Olak J, Herndon J, Richards W, Scalzetti E, Fleishman S, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127:909-15 pubmed
    ..To demonstrate the efficacy, safety, and appropriate mode of instillation of talc for sclerosis in treatment of malignant pleural effusions (MPEs)...
  55. Kamble R, Wilson C, Fassas A, Desikan R, Siegel D, Tricot G, et al. Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma. 2005;46:1137-42 pubmed
    b>Malignant pleural effusion (MPE) in multiple myeloma (MM) is rare. Approximately 80 cases have been reported. To delineate optimal treatment and prognostic variables in these patients, we reviewed 11 MM patients with MPE...
  56. Ohta Y, Shimizu Y, Matsumoto I, Watanabe G. Management of malignant pleural effusion by multimodality treatment including the use of paclitaxel administered by 24-hour intrathoracic infusion for patients with carcinomatous pleuritis. J Exp Clin Cancer Res. 2006;25:15-9 pubmed
    ..infusion as an adjunct to selective surgical management and/or systemic chemotherapy for controlling malignant pleural effusion. Thirteen patients with carcinomatous pleuritis were enrolled in the study between October 2001 and ..
  57. Kilic D, Akay H, Kavukcu S, Kutlay H, Cangir A, Enon S, et al. Management of recurrent malignant pleural effusion with chemical pleurodesis. Surg Today. 2005;35:634-8 pubmed
    b>Malignant pleural effusion is a common complication of primary and metastatic pleural malignancies. It is usually managed by drainage and pleurodesis, but there is no consensus as to the best method of pleurodesis...
  58. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129:362-8 pubmed
    ..Malignant pleural effusions (MPEs) are a common cause of dyspnea in patients with advanced cancer. Tunnelled pleural catheters (TPCs) can be used in patients with this condition, but the published experience with them is limited...
  59. Bernard A, de Dompsure R, Hagry O, Favre J. Early and late mortality after pleurodesis for malignant pleural effusion. Ann Thorac Surg. 2002;74:213-7 pubmed
  60. Nakamoto M, Teramoto H, Matsumoto S, Igishi T, Shimizu E. K-ras and rho A mutations in malignant pleural effusion. Int J Oncol. 2001;19:971-6 pubmed
    ..b>Malignant pleural effusion is a common complication of lung cancer...
  61. Parulekar W, Di Primio G, Matzinger F, Dennie C, Bociek G. Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions. Chest. 2001;120:19-25 pubmed
    ..To evaluate the efficacy of small-bore (12 French vanSonnenberg) catheters compared with standard large-bore chest tubes in the drainage and sclerotherapy of malignant pleural effusions...
  62. Yeh H, Lai W, Chen H, Liu H, Su W. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene. 2006;25:4300-9 pubmed
    b>Malignant pleural effusion (MPE) is a poor prognostic sign for patients with non-small-cell lung cancer (NSCLC)...
  63. Sikora J, Dworacki G, Giersz R, Zeromski J. The role of monocytes/macrophages in TCR-zeta chain downregulation and apoptosis of T lymphocytes in malignant pleural effusions. J Biol Regul Homeost Agents. 2004;18:26-32 pubmed
    ..These data suggest that decreased zeta chain expression in T cells in MPE may be related to the abundance of monocyte/macrophages in effusions...